0001209191-15-037172.txt : 20150429 0001209191-15-037172.hdr.sgml : 20150429 20150429203607 ACCESSION NUMBER: 0001209191-15-037172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150427 FILED AS OF DATE: 20150429 DATE AS OF CHANGE: 20150429 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 15814817 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-04-27 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP\Chief Commercial Officer Common Stock 2015-04-27 4 G 0 150 0.00 D 138120 D Common Stock 2015-04-27 4 M 0 18312 53.74 A 156432 D Common Stock 2015-04-27 4 M 0 15563 45.11 A 171995 D Common Stock 2015-04-27 4 M 0 17000 77.31 A 188995 D Common Stock 2015-04-27 4 S 0 21480 127.49 D 167515 D Common Stock 2015-04-27 4 S 0 12933 128.17 D 154582 D Common Stock 2015-04-27 4 S 0 1100 129.30 D 153482 D Common Stock 2015-04-27 4 S 0 11321 130.33 D 142161 D Common Stock 2015-04-27 4 S 0 4230 131.27 D 137931 D Common Stock 2015-04-27 4 S 0 6316 132.44 D 131615 D Common Stock 2015-04-27 4 S 0 3400 133.34 D 128215 D Common Stock 2015-04-27 4 S 0 700 134.05 D 127515 D Common Stock 140 I 401(k) Stock Option (right to buy) 53.74 2015-04-27 4 M 0 18312 0.00 D 2022-09-03 Common Stock 18312 27188 D Stock Option (right to buy) 45.11 2015-04-27 4 M 0 15563 0.00 D 2023-02-04 Common Stock 15563 45312 D Stock Option (right to buy) 77.31 2015-04-27 4 M 0 17000 0.00 D 2024-02-04 Common Stock 17000 51000 D Represents a gift made to a charitable organization. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $127.49 (range $126.88 to $127.87). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $128.17 (range $127.88 to $128.82). Open market sales reported on this line occurred at a weighted average price of $129.30 (range $128.93 to $129.90). Open market sales reported on this line occurred at a weighted average price of $130.33 (range $129.94 to $130.88). Open market sales reported on this line occurred at a weighted average price of $131.27 (range $130.94 to $131.92). Open market sales reported on this line occurred at a weighted average price of $132.44 (range $131.94 to $132.91). Open market sales reported on this line occurred at a weighted average price of $133.34 (range $132.98 to $133.92). Open market sales reported on this line occurred at a weighted average price of $134.05 (range $133.99 to $134.09). The option vests in 16 quarterly installments from 09/04/2012. The option vests in 16 quarterly installments from 02/05/2013. The option vests in 16 quarterly installments from 02/05/2014. Omar White, Attorney-In-Fact 2015-04-29 EX-24.4_578578 2 poa.txt POA DOCUMENT POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Ian Smith, Michael LaCascia, Omar White and Stephen Migausky of Vertex Pharmaceuticals Incorporated (the "Company"), signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, forms and authentication documents for EDGAR Filing Access; 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents; 3. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; 4. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and 5. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of or transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney is intended to constitute a "confirming statement" for presentation to the Securities and Exchange Commission as contemplated by Instruction 7(a) of Forms 3, 4 and 5. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 25th day of March 2015. /s/ Stuart A. Arbuckle Signature Stuart A. Arbuckle Print Name: